Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Sports Med. 2017 Jan;45(1):82-90. doi: 10.1177/0363546516662455. Epub 2016 Sep 30.

A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.

Author information

1
Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
2
Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida, USA.
3
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
4
Musculoskeletal Center, Yale University School of Medicine, New Haven, Connecticut, USA.

Abstract

BACKGROUND:

Bone marrow aspirate concentrate (BMAC) is increasingly used as a regenerative therapy for musculoskeletal pathological conditions despite limited evidence-based support.

HYPOTHESIS:

BMAC will prove feasible, safe, and efficacious for the treatment of pain due to mild to moderate degenerative joint disease of the knee.

STUDY DESIGN:

Randomized controlled trial; Level of evidence, 2.

METHODS:

In this prospective, single-blind, placebo-controlled trial, 25 patients with bilateral knee pain from bilateral osteoarthritis were randomized to receive BMAC into one knee and saline placebo into the other. Fifty-two milliliters of bone marrow was aspirated from the iliac crests and concentrated in an automated centrifuge. The resulting BMAC was combined with platelet-poor plasma for an injection into the arthritic knee and was compared with a saline injection into the contralateral knee, thereby utilizing each patient as his or her own control. Safety outcomes, pain relief, and function as measured by Osteoarthritis Research Society International (OARSI) measures and the visual analog scale (VAS) score were tracked initially at 1 week, 3 months, and 6 months after the procedure.

RESULTS:

There were no serious adverse events from the BMAC procedure. OARSI Intermittent and Constant Osteoarthritis Pain and VAS pain scores in both knees decreased significantly from baseline at 1 week, 3 months, and 6 months ( P ≤ .019 for all). Pain relief, although dramatic, did not differ significantly between treated knees ( P > .09 for all).

CONCLUSION:

Early results show that BMAC is safe to use and is a reliable and viable cellular product. Study patients experienced a similar relief of pain in both BMAC- and saline-treated arthritic knees. Further study is required to determine the mechanisms of action, duration of efficacy, optimal frequency of treatments, and regenerative potential. Registration: ClinicalTrials.gov record 12-004459.

KEYWORDS:

BMAC; MSC; bone marrow; degenerative joint disease; knee osteoarthritis; stem cells

PMID:
27566242
DOI:
10.1177/0363546516662455
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center